REDWOOD CITY, CA / ACCESSWIRE / May 16, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany: the annual CLI Congress on May 6-7 and Masterclass Münster on May 9-10.
The annual CLI Congress in Germany is regarded as one of the foremost forums in the world addressing the complex condition of critical limb ischemia (CLI). The Congress includes a comprehensive educational agenda on the treatment of patients with this severe form of PAD, with a focus on avoiding amputations.
At the conference, Dr. Arne Schwindt, a vascular surgeon from St. Franziskus Hospital Münster in Germany, gave a podium presentation entitled "OCT-guided atherectomy." Dr. Schwindt is widely recognized as a leading global user and pioneer in the use of Avinger's OCT-guided therapies, including the Pantheris image-guided atherectomy devices. Dr. Schwindt's presentation featured patient cases treated with Pantheris to highlight the advantages of onboard OCT imaging in the preservation of limbs that would otherwise necessitate amputation due to CLI.
Masterclass Münster is an annual regional conference with approximately 200 attendees and an agenda focusing on interventional PAD treatments. In a live case presented to the attendees, Dr. Schwindt demonstrated the advantages of Avinger's image-guided approach for the treatment of complex arterial disease. During the case, Dr. Schwindt used Avinger's Pantheris OCT-guided directional atherectomy device to successfully treat a 79 year-old woman suffering from permanent rest pain of the right foot caused by a total occlusion of the popliteal artery.
Dr. Schwindt noted, "Onboard intravascular guidance at the point of therapy combined with directional plaque removal offers a level of precision unparalleled by other technologies. I have found that Pantheris provides extremely durable and safe outcomes for patients over a sustained period. In the multiple studies I have been involved in and in my daily clinical practice, Avinger's OCT-guided atherectomy devices have proven to be particularly beneficial for the treatment of in-stent restenosis, below-the-knee lesions, and in the ‘no-stent' zones of the popliteal artery. Seeing what I treat from the inside the vessel makes this treatment even more efficient and safe compared to other debulking modalities."
Commenting on the live case, Dr. Schwindt added, "Pantheris allowed me to remove the tissue blocking the artery, while precisely controlling direction of therapy. We examined the patient today after treatment. The perfusion parameters of the foot rose significantly, and the patient is out of pain for the first time in weeks. I could not be more pleased with the outcome of the treatment."
Jeff Soinski, Avinger's President and CEO, commented, "Dr. Schwindt's presentation and live case illustrate the benefits of Avinger's Lumivascular platform, particularly in CLI cases where amputation is a major concern should treatment fail. Avinger's image-guided capabilities are particularly beneficial in these high-stakes cases, as Dr. Schwindt demonstrated to the attendees. This level of precision is accentuated by our new Lightbox 3 imaging console, which combines high-definition imaging and advanced workflows to give Avinger's users one of the most advanced and effective tools for the treatment of CLI cases."
Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger's proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray images as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Matt Kreps Darrow Associates Investor Relations (214) 597-8200 mkreps@darrowir.com
Phil Preuss Chief Marketing Officer Avinger, Inc. (650) 241-7942 pr@avinger.com
View source version on accesswire.com: https://www.accesswire.com/701455/Avinger-Announces-Key-Opinion-Leader-Presentation-and-Live-Case-at-Vascular-Conferences-in-Germany
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
Before you take any new medication, whether prescription or over-the-counter (OTC), it's essential to weigh the potential risks and benefits. If the side effects could cause more harm than they're worth, that's a good reason to talk to your doctor about possible alternatives. In particular, experts are warning that some types of medication may raise your blood pressure, or cause your blood pressure medication to fail—a potentially serious side effect, especially for people already at heightened
Transylyania University graduate Taylen Henry has worked at a rural hospital since 2018. After graduating later this month, she will attend a program specializing in rural medicine and hopes to work as an emergency room doctor.
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
Alzheimer's disease impacts women disproportionately, as both patients and caregivers. Of the 6.5 million Americans currently diagnosed with the disease, almost two-thirds of them are women – a sobering 4.3 million women. Scientists and doctors still do not fully understand why this disease, which is the most common type of dementia, is especially bad for women. Some of this disparity may be explained by women's longer lifespan than men, losing estrogen at menopause, greater brain effects of con
The COVID-19 pandemic in Taiwan has reached a plateau, with cases at a high but stable level, the government said on Friday, as it maintained a policy of gradually easing restrictions and letting the island live with the virus. Health Minister Chen Shih-chung said infections could stay near the current level for a while before declining. The more than 94,800 cases and 126 COVID-related deaths reported for the latest 24 hours were both records, but Chen pointed to the trend.
For a decade, Florida lawmakers have refused to expand eligibility for the public health insurance program, Medicaid, to all low-income adults as prescribed under the Affordable Care Act.
Shoppers returned to the malls of Beijing on Sunday as the Chinese capital relaxed pandemic restrictions after declaring a small but persistent COVID-19 outbreak effectively under control. A partial reopening of stores and offices in Beijing was welcomed by a weary populace and struggling shopkeepers eager for life to return to normal. Coupled with a gradual easing of restrictions in Shanghai, it signaled that the worst is over in the twin outbreaks in China's most prominent cities.
Jeff Bridges' battle with COVID-19 while going through chemotherapy for lymphoma left him "pretty close to dying," the actor has revealed.
Dr. Julian Kim didn’t even know he was at risk of a stroke until it was too late.
Michelle Fishman calls it the “worst-case scenario that you don’t really think through.” After a three-week vacation in Greece, the 52-year-old hotel art consultant from Miami and her husband took pre-departure coronavirus tests required to fly home from overseas. She tested positive, he did not. Although coronavirus travel restrictions have eased across many parts of the world, the United States still requires all international air passengers to present a negative test taken within one day of d
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
The cases, which have so far puzzled health officials, have been reported in 33 different countries since early April.
A Central Florida man survived what doctors call an “exploding heart.”
While many of us optimistically hoped that the coronavirus would be a distant memory at this point, that is hardly the reality. We entered 2022 in one of the worst surges throughout the entire pandemic, with the Omicron variant creating record high infection numbers across the U.S. And despite COVID numbers falling substantially throughout February and March, they are back on the rise again. In the last week, the U.S. has reported an average of almost 110,000 new infections every day, according
To the public, the monkeypox outbreak has echoes of the early days of the COVID-19 pandemic. But scientists say it's not the same at all.
Americans are getting older and needing more colonoscopies. Private equity, seeing a “Golden Age of older rectums,” is buying up gastroenterology practices.
When medical student Cátia Seabra talks to high school classes in Portugal about sexually transmitted infections, her goal is to normalize sexual health education and make sure students don’t feel ...